Patents by Inventor Wubin PAN

Wubin PAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12202822
    Abstract: Disclosed in the present application are a salt form and a crystal form of an S1P1 receptor mediated disease or symptom drug 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid (formula A). Also disclosed in the present invention are a preparation method for the salt form or the crystal form, a pharmaceutical composition of the salt form or the crystal form, and use of the salt form or the crystal form in the preparation of a drug for treating and/or preventing an S1P1 receptor mediated disease or symptom.
    Type: Grant
    Filed: October 6, 2022
    Date of Patent: January 21, 2025
    Assignee: SuZhou Connect Biopharmaceuticals, Inc.
    Inventors: Wei Zheng, Wubin Pan, Jiawang Guo
  • Publication number: 20240190954
    Abstract: Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.
    Type: Application
    Filed: November 15, 2023
    Publication date: June 13, 2024
    Inventors: Wei Zheng, Wubin Pan, Xin Yang, Yang Chen, Limin Zhang, Jie Jiang
  • Patent number: 11866491
    Abstract: Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: January 9, 2024
    Assignee: SuZhou Connect Biopharmaceuticals, Inc.
    Inventors: Wei Zheng, Wubin Pan, Xin Yang, Yang Chen, Limin Zhang, Jie Jiang
  • Publication number: 20230167180
    Abstract: Disclosed is a human IL-4R antibody or an antigen binding fragment thereof. The antibody or the antigen binding fragment thereof specifically binds with human IL-4R? and binds with a specific epitope in human IL-4R?. Moreover, also provided in the present disclosure are uses of the epitope in screening a human IL-4R binding agent or blocking agent for a human IL-4/IL-13 signal transduction pathway or uses in assessing the efficacy of the binding agent or blocking agent by using the specific epitope.
    Type: Application
    Filed: April 19, 2021
    Publication date: June 1, 2023
    Inventors: Xin YANG, Limin ZHANG, Jie JIANG, Jing XIA, Wubin PAN, Wei ZHENG
  • Publication number: 20230050777
    Abstract: Disclosed in the present application are a salt form and a crystal form of an S1P1 receptor mediated disease or symptom drug 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid (formula A). Also disclosed in the present invention are a preparation method for the salt form or the crystal form, a pharmaceutical composition of the salt form or the crystal form, and use of the salt form or the crystal form in the preparation of a drug for treating and/or preventing an S1P1 receptor mediated disease or symptom.
    Type: Application
    Filed: October 6, 2022
    Publication date: February 16, 2023
    Inventors: Wei ZHENG, Wubin PAN, Jiawang GUO
  • Patent number: 11512078
    Abstract: Disclosed in the present application are a salt form and a crystal form of an S1P1 receptor mediated disease or symptom drug 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid (formula A). Also disclosed in the present invention are a preparation method for the salt form or the crystal form, a pharmaceutical composition of the salt form or the crystal form, and use of the salt form or the crystal form in the preparation of a drug for treating and/or preventing an S1P1 receptor mediated disease or symptom.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: November 29, 2022
    Assignee: SUZHOU CONNECT BIOPHARMACEUTICALS, LTD.
    Inventors: Wei Zheng, Wubin Pan, Jiawang Guo
  • Publication number: 20220348666
    Abstract: The present invention provides a liquid composition comprising an antibody of human interleukin-4 receptor alpha. The liquid composition comprises the antibody at a concentration of 50-200 mg/ml ; and a buffer, a protective agent, and a surfactant as adjuvants. The liquid composition has a pH of 5.4-6.4.
    Type: Application
    Filed: March 13, 2020
    Publication date: November 3, 2022
    Inventors: Wei ZHENG, Wubin PAN, Xin YANG, Limin ZHANG, Jie JIANG
  • Publication number: 20210230152
    Abstract: Disclosed in the present application are a salt form and a crystal form of an S1P1 receptor mediated disease or symptom drug 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid (formula A). Also disclosed in the present invention are a preparation method for the salt form or the crystal form, a pharmaceutical composition of the salt form or the crystal form, and use of the salt form or the crystal form in the preparation of a drug for treating and/or preventing an S1P1 receptor mediated disease or symptom.
    Type: Application
    Filed: May 4, 2018
    Publication date: July 29, 2021
    Inventors: Wei ZHENG, Wubin PAN, Jiawang GUO
  • Publication number: 20210079088
    Abstract: Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.
    Type: Application
    Filed: August 14, 2020
    Publication date: March 18, 2021
    Inventors: Wei ZHENG, Wubin PAN, Xin YANG, Yang CHEN, Limin ZHANG, Jie JIANG
  • Patent number: 10774141
    Abstract: Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: September 15, 2020
    Assignee: Suzhou Connect Biopharmaceuticals, Ltd.
    Inventors: Wei Zheng, Wubin Pan, Xin Yang, Yang Chen, Limin Zhang, Jie Jiang
  • Publication number: 20200255514
    Abstract: Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.
    Type: Application
    Filed: March 4, 2020
    Publication date: August 13, 2020
    Inventors: Wei ZHENG, Wubin PAN, Xin YANG, Yang CHEN, Limin ZHANG, Jie JIANG
  • Publication number: 20190177408
    Abstract: Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.
    Type: Application
    Filed: June 8, 2017
    Publication date: June 13, 2019
    Inventors: Wei ZHENG, Wubin PAN, Xin YANG, Yang CHEN, Limin ZHANG, Jie JIANG
  • Patent number: 10280158
    Abstract: The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1P1 receptor.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: May 7, 2019
    Assignee: SUZHOU CONNECT BIOPHARMACEUTICALS, LTD.
    Inventors: Wei Zheng, Wubin Pan, Xin Yang
  • Publication number: 20160347745
    Abstract: The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1P1 receptor.
    Type: Application
    Filed: September 15, 2014
    Publication date: December 1, 2016
    Inventors: Wei ZHENG, Wubin PAN, Xin YANG